Phenylbutyrate increases pyruvate dehydrogenase complex activity in cells harboring a variety of defects

Rosa Ferriero¹, Audrey Boutron², Michele Brivet², Douglas Kerr³, Eva Morava⁴, Richard J. Rodenburg⁵, Luisa Bonafe⁶, Matthias R. Baumgartner⁷, Yair Anikster⁸, Nancy E. Braverman⁹¹⁰ & Nicola Brunetti-Pierri¹¹

¹Telethon Institute of Genetics and Medicine, Naples, Italy
²Laboratoire de Biochimie, AP-HP Hôpital de Bicêtre, Le Kremlin Bicêtre, France
³Center for Inherited Disorders of Energy Metabolism, Case Western Reserve University, Cleveland, Ohio, USA
⁴Hayward Genetics Center, Tulane University Medical School, New Orleans, Louisiana, USA
⁵Department of Pediatrics, Nijmegen Center for Mitochondrial Disorders, Radboud University Medical Center, Nijmegen, The Netherlands
⁶Center for Molecular Diseases, Lausanne University Hospital, Lausanne, Switzerland
⁷Division for Metabolic Diseases and Children’s Research Center, University Children's Hospital, Zürich, Switzerland
⁸Metabolic Disease Unit, Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Tel-Hashomer and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
⁹Department of Human Genetics, McGill University, Montreal, Quebec, Canada
¹⁰Department of Pediatrics, Montreal Children’s Hospital Montreal, Montreal, Quebec, Canada
¹¹Department of Translational Medicine, Federico II University of Naples, Naples, Italy

Abstract

Objective: Deficiency of pyruvate dehydrogenase complex (PDHC) is the most common genetic disorder leading to lactic acidosis. PDHC deficiency is genetically heterogenous and most patients have defects in the X-linked E1-α gene but defects in the other components of the complex encoded by PDHB, PDHX, DLAT, DLD genes or in the regulatory enzyme encoded by PDP1 have also been found. Phenylbutyrate enhances PDHC enzymatic activity in vitro and in vivo by increasing the proportion of unphosphorylated enzyme through inhibition of pyruvate dehydrogenase kinases and thus, has potential for therapy of patients with PDHC deficiency. In the present study, we investigated response to phenylbutyrate of multiple cell lines harboring all known gene defects resulting in PDHC deficiency. In the present study, we investigated response to phenylbutyrate of multiple cell lines harboring all known gene defects resulting in PDHC deficiency. Methods: Fibroblasts of patients with PDHC deficiency were studied for their enzyme activity at baseline and following phenylbutyrate incubation. Drug responses were correlated with genotypes and protein levels by Western blotting. Results: Large deletions affecting PDHA1 that result in lack of detectable protein were unresponsive to phenylbutyrate, whereas increased PDHC activity was detected in most fibroblasts harboring PDHA1 missense mutations. In the prospect of a clinical trial, the results of this study may allow prediction of in vivo response in patients with PDHC deficiency harboring a wide spectrum of molecular defects.
Introduction

Deficiency of nuclear-encoded pyruvate dehydrogenase complex (PDHC) is one of the most common inborn errors of mitochondrial energy metabolism. PDHC catalyzes within mitochondria conversion of pyruvate to acetyl coenzyme A, a key regulatory step in the central pathway of energy production. This reaction is particularly important in brain which has obligatory requirement for aerobic glucose oxidation. Most patients with PDHC deficiency show progressive neurological degeneration and either persistent or episodic elevations of lactate in blood, cerebrospinal fluid (CSF), or both. Affected patients present with a graded spectrum of severity ranging from the most severe congenital brain malformations with overwhelming lactic acidemia and death in the neonatal period to development of Leigh syndrome or to a milder form with carbohydrate induced ataxia. PDHC is a mutienzyme complex consisting of (1) thiamine diphosphate (ThDP)-dependent pyruvate dehydrogenase (E1), a heterotetrameric (α₂β₂) protein; (2) dihydrolipoamide acetyltransferase (E2), which forms the structural core of the complex; and (3) FAD-containing dihydrolipoamide dehydrogenase (E3), which is integrated into the complex by an E3-binding protein (E3BP). PDHC is regulated through phosphorylation of E1-α subunit by four pyruvate dehydrogenase kinase (PDK) isoforms that inactivate the enzyme, whereas dephosphorylation by pyruvate dehydrogenase phosphatases (PDP1 and PDP2) restore PDHC activity. PDHC deficiency may be due to mutations in the genes PDHA1, PDHB, PDHX, DLAT, and DLD encoding for E1-α, E1-β, E3BP, E2, and E3, respectively, or to mutations of PDPI gene encoding pyruvate dehydrogenase phosphatase 1. The most common form is due to mutations of PDHA1 gene located on the short arm of the X chromosome. We have previously shown that phenylbutyrate increases residual activity of PDHC by increasing the proportion of unphosphorylated enzyme and has potential for therapy of PDHC deficiency and systemic lactic acidosis. In the present study, to correlate in vitro drug response to the type of mutation, we investigated phenylbutyrate responsiveness on several cell lines harboring PDHA1 mutations. In addition, we investigated phenylbutyrate response in patients’ fibroblasts harboring defects in all remaining components of the multifienzyme complex and in PDPI gene.

Material and Methods

PDHC activity was measured at baseline and after incubation with 1 mmol/L phenylbutyrate (Amonaps; Swedish Orphan International Lab, Stockholm, Sweden) in Dulbecco’s Modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum (FBS) for 24 h or 5 days on mitochondrial extracts prepared from synchronized fibroblasts (cultured in DMEM and 1% FBS for 24 h), as previously described. PDHC enzyme activity was calculated as nmol min⁻¹ mg⁻¹ of protein and expressed as fold increase of activity in cells treated with phenylbutyrate over untreated cells (at least n = 2 for each treatment). Statistical significance was computed using the Student’s two-tailed test. P < 0.05 was considered statistically significant.

Fibroblasts were analyzed for expression of proteins of PDHC with the following primary monoclonal antibodies: anti-PDH-E1α (9H9AF5), anti-PDH-E1β (17A5E2H8), anti-PDH-E2 (15D3G9C11), anti-E3BP (13G2AE2H5), and anti-PDH-E3 (EPR6635). The anti-PDH-E1α, anti-PDH-E1β, anti-PDH-E2, anti-E3BP mixed in a cocktail (#ab110416), and the anti-PDH-E3 (#ab133551) were purchased from Abcam (Cambridge, UK). The antibodies phosphodetekt anti-PDH-E1α (pSer264; AP1062), phosphodetekt anti-PDH-E1β (pSer203; AP1063), phosphodetekt anti-PDH-E1ξ (pSer271; AP1064) were from Calbiochem (Darmstadt, Germany) and the anti-cytchrome c oxidase IV (COXIV; #4844) from Cell Signaling Technology Inc (Danvers, MA, USA). Horseradish peroxidase (HRP)-conjugated secondary antibodies (ECL rabbit IgG, HRP-linked whole antibody from donkey [GE Healthcare, Milan, Italy NA934] and ECL anti-mouse IgG, HRP-linked species-specific whole antibody from sheep [GE Healthcare, NA931]) were diluted in 5% dried skim milk and in 1% bovine serum albumin (BSA) in tris-buffered saline-Tween20. Protein bands were visualized with a chemiluminescence detection system (Thermo Fisher Scientific Inc., Rockford, IL, USA) and band intensities were quantified with Quantity One-4.6.7 Basic (1-D Analysis Software; Bio-Rad Laboratories Inc. Hercules, CA, USA).

For proteasome inhibition, cells were cultured in DMEM supplemented with 10% FBS and after the 5-day treatment with 1 mmol/L of phenylbutyrate, were incubated with 40 μmol/L MG132 (Selleckchem, Munich, Germany) or Dimethyl Sulfoxide (DMSO) for 6 h, washed once with cold phosphate-buffered saline (PBS), and scraped with RIPA buffer (50 mmol/L Tris-HCl pH 7.4, 150 mmol/L NaCl, 1% Triton X-100, 1 mmol/L Ethylenediaminetetraacetic acid (EDTA) pH 8.0, 0.1% SDS) containing complete protease inhibitor cocktail (Sigma, St. Louis, MO, USA). Samples were incubated for 20 min at 4°C, centrifuged at 16,000 g for 10 min and cell lysates were used for Western blot.

Results

We analyzed PDHC activity in untreated and phenylbutyrate-treated skin fibroblasts from patients harboring all
Table 1. PDHC-deficient fibroblasts.

<table>
<thead>
<tr>
<th>Cell line</th>
<th>Gender</th>
<th>Enzyme activity (% mean control)</th>
<th>Allele 1 nucleotide (protein)</th>
<th>Allele 2 nucleotide (protein)</th>
</tr>
</thead>
<tbody>
<tr>
<td>PDHA1 mutations</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1b</td>
<td>Male</td>
<td>62%</td>
<td>c.749C&gt;T (p.Q263X)</td>
<td>–</td>
</tr>
<tr>
<td>2c</td>
<td>Male</td>
<td>46%</td>
<td>c.787C&gt;G (p.R263G)</td>
<td>–</td>
</tr>
<tr>
<td>3b</td>
<td>Male</td>
<td>56%</td>
<td>c.832G&gt;C (p.G277R)</td>
<td>–</td>
</tr>
<tr>
<td>4c</td>
<td>Male</td>
<td>21%</td>
<td>c.1132G&gt;C (p.R378C)</td>
<td>–</td>
</tr>
<tr>
<td>5b</td>
<td>Male</td>
<td>45%</td>
<td>c.1132C&gt;T (p.R378H)</td>
<td>–</td>
</tr>
<tr>
<td>6b</td>
<td>Male</td>
<td>7%</td>
<td>c.1133G&gt;A (p.R378D)</td>
<td>–</td>
</tr>
<tr>
<td>7b</td>
<td>Male</td>
<td>18%</td>
<td>c.1133G&gt;A (p.R378D)</td>
<td>–</td>
</tr>
<tr>
<td>8d</td>
<td>Male</td>
<td>52%</td>
<td>c.483C&gt;T (p.Y159C)</td>
<td>–</td>
</tr>
<tr>
<td>9b</td>
<td>Male</td>
<td>7%</td>
<td>c.1050_1133dup84 (p.Q351_R378dup)</td>
<td>–</td>
</tr>
<tr>
<td>10</td>
<td>Female</td>
<td>47%</td>
<td>c.302G&gt;T (p.C72F)</td>
<td>wt</td>
</tr>
<tr>
<td>11a</td>
<td>Female</td>
<td>48%</td>
<td>c.302G&gt;T (p.C72F)</td>
<td>wt</td>
</tr>
<tr>
<td>12a</td>
<td>Female</td>
<td>30%</td>
<td>c.355C&gt;T (p.R98V)</td>
<td>wt</td>
</tr>
<tr>
<td>13a</td>
<td>Female</td>
<td>23%</td>
<td>c.379C&gt;T (p.R98V)</td>
<td>wt</td>
</tr>
<tr>
<td>14a</td>
<td>Female</td>
<td>83%</td>
<td>c.787C&gt;G (p.R263G)</td>
<td>wt</td>
</tr>
<tr>
<td>15</td>
<td>Female</td>
<td>13%</td>
<td>c.904C&gt;T (p.R272C)</td>
<td>wt</td>
</tr>
<tr>
<td>16a</td>
<td>Female</td>
<td>21%</td>
<td>c.904C&gt;T (p.R272C)</td>
<td>wt</td>
</tr>
<tr>
<td>17a</td>
<td>Female</td>
<td>19%</td>
<td>c.904T&gt;C (p.R272S)</td>
<td>wt</td>
</tr>
<tr>
<td>18a</td>
<td>Female</td>
<td>57%</td>
<td>c.924G&gt;T (p.Q279R)</td>
<td>wt</td>
</tr>
<tr>
<td>19a</td>
<td>Female</td>
<td>35%</td>
<td>c.498C&gt;T (p.R161C)</td>
<td>wt</td>
</tr>
<tr>
<td>20a</td>
<td>Female</td>
<td>8%</td>
<td>c.292-2A&gt;G (p.E98_Q170del)</td>
<td>wt</td>
</tr>
<tr>
<td>21</td>
<td>Female</td>
<td>38%</td>
<td>c.1140_1162del (p.N381fsX43)</td>
<td>wt</td>
</tr>
<tr>
<td>22a</td>
<td>Female</td>
<td>22%</td>
<td>c.934_940del (p.S312fsX112)</td>
<td>wt</td>
</tr>
<tr>
<td>23b</td>
<td>Female</td>
<td>19%</td>
<td>2.14 Mb deletion</td>
<td>wt</td>
</tr>
<tr>
<td>PDHB mutations</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>24b</td>
<td>Male</td>
<td>75%</td>
<td>c.301A&gt;G (p.M101V)</td>
<td>c.301A&gt;G (p.M101V)</td>
</tr>
<tr>
<td>25b</td>
<td>Male</td>
<td>70%</td>
<td>c.301A&gt;G (p.M101V)</td>
<td>c.301A&gt;G (p.M101V)</td>
</tr>
</tbody>
</table>

(Continued)
splicing (c.483C>T), or truncating (p.Q351_R378dup) mutations were studied (Table 1, black bars in Fig. 1A). Hemizygous cell lines from patients carrying missense mutations p.P221L, p.R234G, and p.G249R (cell lines 1, 2, and 3) showed elevated PDHC activities (62%, 46%, and 56% of control mean), detectable E1-\(\alpha\) protein by Western blotting, and were all responsive to phenylbutyrate (Fig. 1A and B, and Table 1). Four cell lines not responsive to phenylbutyrate all carried \(PDHA1\) missense mutations affecting the R349-\(\alpha\) residue, had relatively lower levels of PDHC residual activity ranging from 7% to 45%, and showed very low-to-undetectable levels of protein E1-\(\alpha\) by Western blotting, and were all responsive to phenylbutyrate (Fig. 1A and B, and Table 1). Four cell lines not responsive to phenylbutyrate all carried \(PDHA1\) missense mutations affecting the R349-\(\alpha\) residue, had relatively lower levels of PDHC residual activity ranging from 7% to 45%, and showed very low-to-undetectable levels of protein E1-\(\alpha\) by Western blotting, and were all responsive to phenylbutyrate (Fig. 1A and B, and Table 1). Lack of increase in PDHC activity following phenylbutyrate incubation was also previously observed in another cell line (designated as Pt 3) from an unrelated patient also harboring a mutation affecting R349-\(\alpha\). It was previously shown that cells harboring the p.R349C mutation were also unresponsive to short-term incubation with dichloroacetate (DCA), a pyruvate analog which increases PDHC activity. In contrast, sustained DCA incubation reduced turnover of E1-\(\alpha\) protein and increased PDHC activity. Therefore, we investigated longer incubation with phenylbutyrate in fibroblasts harboring mutations affecting R349-\(\alpha\) (cell lines 4–7 and Pt 3) and found that 5-day drug incubation increased PDHC enzyme activity (Fig. 2A). Following 5-days of incubation with phenylbutyrate, we also observed an increase in the amount of E1-\(\alpha\) protein compared to untreated cells (Fig. 2B). The ubiquitin-proteasome is the major route for degradation of cell proteins and thus, we investigated E1-\(\alpha\) protein levels in fibroblast cell line 5, carrying the p.R349C mutation, by inhibiting proteasome activity with the MG132 proteasome inhibitor. Incubation with MG132 increased E1-\(\alpha\) protein to levels similar to those observed in phenylbutyrate-treated cells but no further increase in E1-\(\alpha\) was observed in cells cotreated with phenylbutyrate and MG132 (Fig. 2B). Taken together, these results may indicate that E1-\(\alpha\) harboring the p.R349C mutation is degraded by the proteasome and phenylbutyrate increases resistance of the mutated protein to proteasome degradation.

The synonymous mutation c.483C>T (p.Y132Y) of cell line 8 causes aberrant splicing in 40% of total cDNA with exon 5 skipping predicted to result in a frameshift and premature termination after the addition of 10 aberrant amino acids (p.Arg141AlafsX11). Immunoblotting of these fibroblasts resulted in detectable E1-\(\alpha\) protein band...
of normal size expressed from the proportion of correctly spliced mRNA (Fig. 1A). Phenylbutyrate likely increased enzyme activity of normal E1-α enzyme expressed from the correctly spliced mRNA. The hemizygous cell line 9 from male patient carrying the c.1050_1133dup84 resulted in very low PDHC activity, in no detectable E1-α protein, and phenylbutyrate failed to increase significantly PDHC activity (Fig. 1A and B).

Fibroblasts from 14 female patients harboring missense (p.C72F, p.R90W, p.R98W, p.R234G, p.R273C, p.Q279H), splicing (c.498C>T), or truncating (p.E98_Q170del, p.S312VfsX12, p.N381SfsX43, 2.15 Mb deletion) mutations were studied (Table 1, white bars in Fig. 1A). Cell lines with PDHA1 mutations from female patients are expected to express both wild-type and mutant alleles. Furthermore, skewed X-inactivation is found in approximately one fourth of skin fibroblasts from PDHC-deficient patients. Thus, PDHC activity in cells from female patients results from both residual activity of the enzyme encoded by the mutant allele and the activity of the enzyme expressed from the wild-type allele. Cell line harboring the p.Q279H mutation showed low levels of E1-α protein by Western blotting and was unresponsive to phenylbutyrate (cell line 18, Fig. 1A and B).

Figure 2. (A) PDHC activity in fibroblasts with mutations affecting R349 residue of E1-α protein following shorter (1 day) and longer (5 days) phenylbutyrate incubations. (B) Western blotting for E1-α (43 kDa), E1-β (39 kDa), and E2 (69 kDa) protein of cell line 5 harboring p.R349C mutation incubated with either vehicle, phenylbutyrate, MG132, or a combination of phenylbutyrate and MG132. Cytochrome c oxidase (COX; 17 kDa) was used as mitochondrial control marker.
So far, 12 PDHB mutations have been reported and four mutations, including the p.M101V found in patients of North African descent, clustered in the same region. We investigated phenylbutyrate in four cell lines from patients harboring PDHB mutations (cell lines 24–27, Table 1) including the p.M101V mutation, and three of them showed a statistically significant increase in PDHC activity after phenylbutyrate incubation (Fig. 3A). Three of these cell lines with PDHB mutations showed a reduction in E1-β protein by Western blotting, whereas the nonresponder cell line (cell 27) had E1-β levels similar to wild-type levels (Fig. 3B). In two of the three cell lines responding to phenylbutyrate in terms of increased enzyme activity (cell lines 24 and 25), an increase in E1-β protein was observed by Western blotting after phenylbutyrate incubation (Fig. 3B). In the three cell lines that responded to phenylbutyrate in terms of increased PDHC activity, a reduction in phosphorylated E1-α levels was observed, whereas cell line 27 that failed to respond to phenylbutyrate did not show a reduction in phosphorylated E1-α levels (Figs. 3B, S1).

The E3BP lacks catalytic activity and has a structural role in the formation of the enzyme complex binding E3 to E2. Mutations in PDHX gene encoding E3BP are the second most common cause of PDHC deficiency and the vast majority of the mutations are aberrant splicing or nonsense mutations. In this study, we investigated five cell lines harboring mutations in PDHX gene that all carried nonsense mutations or deletions and showed enzyme activity ranging from 14% to 41% (cell lines 28–32, Table 1, Fig. 3A and C). Two of the cell lines (31 and 32, Table 1) harboring a single nucleotide deletion leading to frameshift or an exon 4 and 5 deletion did not show detectable E3BP by Western blotting (Fig. 3C). All five
One cell line with DLAT mutation was available for analysis and a 1.3-fold increase enzyme activity was detected in this cell line after incubation with phenylbutyrate (cell line 33, Table 1 and Fig. 3A). Fibroblasts of cell line 33 had low enzyme activity and did not show detectable levels of E2 protein by Western blotting even after incubation with phenylbutyrate (Fig. 3D). Only one mutation was detected in this patient. It appears that mutations in the gene encoding the E2 are rare cause of PDHC deficiency.2,15–17 One patient previously reported had undetectable E2 immunoreactive protein,16 whereas two other patients were found to express reduced but detectable levels of E2 protein.17 The clinical presentation appeared to be more severe in the patient with undetectable E2 protein compared to the patients with detectable E2 that had relatively mild symptoms and episodic dystonia. DCA was previously shown to increase PDHC activity in fibroblasts of these patients with DLAT mutations.17 Phenylbutyrate was also found to correct the morphological, locomotor, and behavioral phenotype of the noa<sup>DLAT</sup> zebrafish model carrying a missense DLAT gene mutation.7 Thus, E2 defects resulting from DLAT mutations appear to be responsive to phenylbutyrate. A reduction in phosphorylated E1<sub>x</sub> levels was observed in this cell line with DLAT mutation following phenylbutyrate incubation (Figs. 1, 3B).

We also investigated phenylbutyrate in two cell lines harboring DLD mutations resulting in E3 deficiency and both showed an average 1.4-fold increase in baseline PDHC activity (cell lines 34 and 35, Table 1 and Fig. 3A). Both cell lines expressed the E3 protein, as shown by Western blotting with anti-E3 antibody (Fig. 3E). Clinical and biochemical presentation of this disorder is different from the common presentation of other PDHC defects.18,19 E3 is a common component of all three mitochondrial multienzyme complexes, and DLD mutations result in a disorder associated with a combination of features of branched chain α-ketoacid dehydrogenase (BCKDC), PDHC, and α-ketoglutarate dehydrogenase complex (KGDC) deficiencies. Phenylbutyrate inhibits the kinase of BCKDC (BDK) and PDKs<sup>7,20</sup> and thus, it is expected to result in improvements of both BCKDC and PDHC activities. Like cell lines with other defects, a reduction in phosphorylated E1<sub>x</sub> levels was observed in cells with DLD mutations (Figs. 3B, S1).

Finally, we investigated one cell line with PDP1 mutations that was found to respond to phenylbutyrate (cell line 36, Table 1; Fig. 3A). Phosphorylation of E1-α occurs at three serine residues (Ser264-α, site 1; Ser271-α, site 2; and Ser203-α, site 3). As expected based on the deficiency of the phosphatase activity, the amount of phosphorylated E1-α in this cell line is increased compared to control wild-type cell lines (Fig. 3F). Following phenylbutyrate incubation, phosphorylated E1-α was significantly reduced at all three phosphorylation sites (Fig. 3F) that is consistent with the mechanism of action of phenylbutyrate based on PDK inhibition.<sup>7</sup>

**Discussion**

Phenylbutyrate enhances PDHC activity in vitro and in vivo by increasing the proportion of unphosphorylated enzyme through inhibition of PDK. It also reduces lactic acid in a mouse model of systemic lactic acidosis, and rescues the phenotype of a zebrafish PDHC-deficient disease model.7 In the present study, we investigated the efficacy of phenylbutyrate in PDHC-deficient cells harboring a wide spectrum of genetic defects and we correlated genotypes with drug response. We found that phenylbutyrate increases PDHC activity in the majority of analyzed fibroblasts. Increased PDHC activity was detected in most of the fibroblasts with PDHA1 missense mutations. Large deletions or nonsense PDHA1 mutations resulting in no detectable protein by Western blotting were in general not responsive to phenylbutyrate. The gene encoding E1-α is located on the X chromosome, yet males and females are affected in approximately equal numbers due to the high proportion of heterozygous females manifesting the disease. All male patients with PDHA1 mutations have some degree of residual activity, whereas several female patients have null mutations resulting in complete deficiency of the enzyme subunit. It appears that complete PDHC deficiency is incompatible with normal development in hemizygous males but can be tolerated in heterozygous females due to the proportion of cells expressing the normal X chromosome. In cells from female patients, due to skewed pattern of X-inactivation favoring the normal X chromosome, enzyme activity might be higher, even falling within the normal range. In this context, the great majority of mRNA molecules arise from the normal gene. Phenylbutyrate increases PDHC activity in wild-type cells<sup>7</sup> and thus, it is not possible to determine in cells from female patients whether phenylbutyrate increases the activity of the enzyme encoded by the wild-type or by the mutated allele. Nevertheless, we cannot rule out that even an increase in PDHC activity in cells expressing the normal allele might be beneficial in patients with PDHC deficiency.

Cells harboring mutations affecting the R349-α residue of the E1-α protein were consistently found to be unresponsive to short-term incubation with phenylbutyrate.
but longer incubations resulted in increased activity. These results indicate that in addition to the direct effect on PDK, phenylbutyrate increases the stability of E1-α protein, at least in cells harboring missense mutations affecting the R349-α. This result is consistent with the previously recognized function of phenylbutyrate as chemical chaperone and with reduced E1-α protein turnover observed with sustained DCA incubation in addition to PDK inhibition by DCA.

We found that mutations affecting PDHB, PDHX, DLAT, and DLD genes were also responsive, thus potentially broadening therapeutic applications of phenylbutyrate to patients that harbor all known defects of PDHC deficiency. In these cell lines a reduction in phosphorylated E1-α protein levels was observed by Western blotting, thus suggesting that like cells with PDHA1 mutations, the increase in enzyme activity in cells harboring these defects is dependent, at least in part, on changes of phosphorylation status of the enzyme complex induced by phenylbutyrate.

Similar to phenylbutyrate, DCA also increases PDHC activity and is effective in reducing blood, CSF, and brain lactate. However, in a controlled trial in children with various forms of congenital lactic acidosis, chronic DCA administration did not result in improvements of neurologic problems and other clinical outcomes. Moreover, DCA has raised some concerns because it has been associated with hepatocellular and peripheral nerve toxicity, particularly in adults. In contrast, phenylbutyrate is a drug already approved for use in humans, its safety profile is well known, and thus it is attractive for therapy of patients with PDHC deficiency.

Enzyme activity measured in skin fibroblasts exhibit large variations among PDHC-deficient patients and does not correlate with the predicted severity of the mutation and cognitive outcomes, either in males or females. Nevertheless, enzyme activity appears to correlate with survival at least in males with PDHA1 mutations and thus, drug interventions aiming at increasing enzyme residual activity have potential for achieving clinically relevant results. However, it is unlikely that such drug interventions will reverse pre-existing severe brain damage, such as Leigh syndrome.

In summary, cells harboring PDHA1 gene mutations, that are the most common defects accounting for 80–90% of cases of PDHC deficiency with known mutations, respond to phenylbutyrate, especially if they carry missense mutations, have PDHC activity >10%, or exhibit detectable protein by Western blotting. Therefore, patients carrying these defects are candidates for such drug intervention. Cell lines from patients carrying other less common molecular defects also appear to be responsive to phenylbutyrate.

In conclusion, the results of the present study may help to predict whether a patient with PDHC deficiency will be responsive to phenylbutyrate therapy based on the affected gene, type, and location of the mutation.

Acknowledgments

This work was supported by grants of the European Research Council (IEMTx to N. B.-P.), United Mitochondrial Disease Foundation (to N. B.-P.), and Italian Telethon Foundation (P37TELC to N. B.-P.).

Authors Contributions

R. Ferriero performed all experiments included in the study. A. Boutron, M. Brivet, D. Kerr, E. Morava, R. J. Rodenburg, L. Bonafé, M. R. Baumgartner, Y. Anikster, and N. E. Braverman provided fibroblast cell lines from PDHC-deficient patients with molecular diagnoses. N. Brunetti-Pierri designed and supervised the study.

Conflict of Interest

None declared.

References

8. DeVivo DC, Haymond MW, Obert KA, et al. Defective activation of the pyruvate dehydrogenase complex in...
Phenylbutyrate and PDHC Deficiency

R. Ferriero


Supporting Information

Additional Supporting Information may be found in the online version of this article:

Figure S1. Average intensities of Western blotting bands of phosphorylated E1-z normalized for total E1-z from two independent experiments of fibroblasts with PDHB, PDHX, DLAT, and DLD mutations (Table 1) incubated with phenylbutyrate or vehicle. *P < 0.05.